Benzinga · Aug 7, 2026
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.
IR
NASDAQ · IRD
Opus Genetics, Inc.
Healthcare · Biotechnology
$3.85
Down-$0.15 (-3.77%)
Updated Aug 28, 2026, 7:41 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 167.86M
- P/E ratio
- -2.65
- Dividend yield
- 0.00%
- 52-week range
- $1.17 – $5.81
- Volume
- 547.54K
- Avg. volume
- 528.52K
Price performance
IRD price history
1M range · 21 trading sessions · Daily adjusted prices
IRD closed at $3.85 after 21 trading sessions, up 0.26% for the selected period.
- Last close
- $3.85
- Period change
- +0.26%
- Period low
- $3.61
- Period high
- $4.12
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $3.80 | $3.92 | $3.79 | $3.85 | 547.54K |
| Aug 26, 2026 | $4.17 | $4.21 | $3.77 | $3.80 | 908.74K |
| Aug 25, 2026 | $4.07 | $4.42 | $4.035 | $4.11 | 1.5M |
| Aug 24, 2026 | $4.02 | $4.2381 | $3.82 | $4.03 | 812.17K |
| Aug 21, 2026 | $4.16 | $4.33 | $4.02 | $4.05 | 1.05M |
| Aug 20, 2026 | $4.01 | $4.26 | $4.005 | $4.12 | 1.46M |
| Aug 19, 2026 | $3.76 | $4.08 | $3.76 | $4.07 | 732K |
| Aug 18, 2026 | $3.65 | $3.71 | $3.585 | $3.69 | 752.88K |
| Aug 17, 2026 | $3.60 | $3.7501 | $3.55 | $3.65 | 608.37K |
| Aug 14, 2026 | $3.74 | $3.75 | $3.56 | $3.61 | 414.48K |
| Aug 13, 2026 | $3.78 | $3.865 | $3.70 | $3.72 | 513.35K |
| Aug 12, 2026 | $3.90 | $3.99 | $3.745 | $3.76 | 480.42K |
| Aug 11, 2026 | $3.67 | $3.91 | $3.60 | $3.88 | 538.4K |
| Aug 10, 2026 | $3.63 | $3.78 | $3.6162 | $3.66 | 608.17K |
| Aug 7, 2026 | $3.73 | $3.75 | $3.525 | $3.66 | 915.17K |
| Aug 6, 2026 | $3.74 | $3.96 | $3.55 | $3.72 | 681.11K |
| Aug 5, 2026 | $3.74 | $3.82 | $3.58 | $3.78 | 872.25K |
| Aug 4, 2026 | $3.67 | $3.72 | $3.605 | $3.71 | 718.46K |
| Aug 3, 2026 | $3.72 | $3.785 | $3.54 | $3.64 | 1.73M |
| Jul 31, 2026 | $3.862 | $3.862 | $3.62 | $3.71 | 970.58K |
| Jul 30, 2026 | $3.46 | $3.875 | $3.4201 | $3.84 | 1.04M |
Latest IRD news
The latest Smart Investors Daily articles mentioning IRD.
Stock researchCompany · Overview
IRD research
Overview
Company profile and research snapshot.
Company profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Jul 29, 2026 | TD Cowen | Buy | — |
| Jul 6, 2026 | BTIG | Buy | — |
| Jul 6, 2026 | Chardan Capital | Buy | — |
| Jun 18, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares
Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock Issuable Upon Exercise ofWarrants and Pre-Funded Warrants Offered, from time to time, by OpusGenetics, Inc.
Benzinga · Aug 6, 2026
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the
Benzinga · Aug 3, 2026
Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease
Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may submit a BLA based on
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
